Ingersoll Rand (IR)'s valuation has been a topic of interest following the rotation into defensive industrial stocks. Notably, there have been changes in stock holdings by SG Americas Securities LLC and Robeco Schweiz AG.
Citi has maintained a 'buy' rating on IR with a target price of $98. The company's stock has seen an increase of 7.2% after defense rotation and the announcement of a deal with Scinomix Life Sciences. IR's organic growth softer growth, it's increasingly focusing on bolt-on M&A.
Nordea Investment Management AB and Robeco Institutional Asset Management B.V. have increased their stakes in IR, while Swedbank AB has purchased a significant number of shares. The company's Q3 earnings were in line with analyst expectations, but there was a subsequent drop in stock price. The appointment of Jerome Guillen to the board has led to a reassessment of IR's valuation. IR has also acquired
Scinomix, which solidifies their life sciences portfolio, and BoD welcomes Jerome Guillen. As IR approaches Q3 earnings, there are concerns about the balance sheet. Despite some pessimistic views about IR's stock, it's been noted that returns are on the way up.
Ingersoll Rand IR News Analytics from Tue, 08 Apr 2025 07:00:00 GMT to Fri, 16 Jan 2026 14:17:54 GMT -
Rating 2
- Innovation 3
- Information 7
- Rumor 1
